This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


John A. Hohneker
CEO and President at Anokion


Dr. Hohneker joined Anokion in January 2018 from Forma Therapeutics where he was President of Research and Development and led the advancement of multiple programs into the clinic. Previously, he held several leadership positions at Novartis, most recently as Senior Vice President and Global Head of Development for Immunology and Dermatology. At Novartis, Dr. Hohneker played a key role in the development, approval and commercialization of multiple products, including Cosentyx®, Xolair®, Ilaris®, Gleevec®, Tasigna®, Zometa®, Afinitor®, and Exjade®. Earlier in his career, he held positions of increasing responsibility at Glaxo Wellcome and its predecessor Burroughs Wellcome. Dr. Hohneker currently serves on the Board of Directors at Torque Therapeutics and previously served on the Board of Directors at Dimension Therapeutics until its acquisition by Ultragenyx Pharmaceutical in 2017. He received a BA from Gettysburg College, a MD from Rutgers School of Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey-Rutgers Medical School) and completed an internship/residency in internal medicine and a fellowship in medical oncology at UNC Hospitals.

John A. Hohneker's Network

Agenda Sessions

  • Autoimmune and Inflammatory Disease (AIID): Beyond the sledgehammer approach - Hilton Union Square